Cemiplimab nel CSCC, importanti novità da ASCO 2020

[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] Cemiplimab in the treatment of cutaneous squamous cell carcinoma (CSCC): what data from the follow-up observation presented at ASCO 2020? We asked Paola Queirolo, Director of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors at the European Institute of Oncology (IEO) in Milan, who also commented on the initial quality-of-life data presented in this area and the new perspectives for treatment in the adjuvant setting.